Intuitive Surgical, Inc. vs Northrop Grumman Corporation — how do they compare? Intuitive Surgical, Inc. trades at $425.1 (market cap $146.76B), while Northrop Grumman Corporation trades at $481.99 (market cap $68.83B). The key difference: Intuitive Surgical, Inc. is far larger — about 2.1× Northrop Grumman Corporation's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Northrop Grumman Corporation for 81 Days on average.
| ISRG | NOC | |
|---|---|---|
Market Cap | $146.76B | $68.83B |
Volume | 2,529,814 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $592.85 | $768.02 |
52-Week Low | $332.02 | $473.46 |
Typical Hold Time | 84 Days | 81 Days |
Enterprise Value | $141.54B | $82.81B |
Dividend Yield | — | 2.04% |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $414.52, up 2.41% today, with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with revenue growth from $6.2B in 2022 to $10.1B in 2025 and net income margin expanding to 28.45%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.80 surpassing the $2.48 forecast.
ISRG maintains a dominant position in robotic surgery with expanding international growth, though valuation multiples remain elevated with a P/E of 47.64. Analyst consensus is strongly bullish with a $480.78 price target representing 16% upside potential. Key risks include competitive pressures and international market volatility, particularly in China.
Northrop Grumman (NOC) trades at $479.00, up 1.17% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $7.68 exceeding expectations, supported by a robust $104.7 billion backlog and expanding defense budgets. Recent news highlights both competitive pressures from Boeing's $20B fighter contract win and positive developments in F-35 radar demand.
The investment outlook remains positive with analyst consensus at $600.62 (25% upside) and 54% buy ratings, though technical indicators suggest near-term pressure. Key risks include contract competition and execution challenges on major programs like the B-21 bomber, while strong cash flow generation and dividend growth provide shareholder support.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →